Trials / Completed
CompletedNCT04393220
Combination of PD-1 and VEGFR-2 Blockade for Advanced Hepatocellular Carcinoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 60 (actual)
- Sponsor
- Fuda Cancer Hospital, Guangzhou · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The aie of this clinical study is the safety and efficacy of combination therapy for HCC patients.
Detailed description
Activation of anti-tumor immune response using programmed death receptor-1 (PD-1)blockade showed benefit only in a fraction of hepatocellular carcinoma (HCC) patients. Specific blockade of vascular endothelial receptor 2 (VEGFR-2) using a murine antibody significantly delayed primary tumor growth but failed to prolong survival. Combining PD-1 blockade with antiangiogenesis has shown promise in substantially increasing the fraction of HCC patients who respond to treatment in vitro. Based on these clinical data, we are aimed to investigation the safety and efficacy of combination therapy for HCC patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bevacizumab Injection | 15mg/kg (Q3W) |
| DRUG | Nivolumab | nivolumab 480 mg IV infusions for 30 minutes q4w |
Timeline
- Start date
- 2020-05-11
- Primary completion
- 2021-07-30
- Completion
- 2021-08-31
- First posted
- 2020-05-19
- Last updated
- 2021-09-05
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04393220. Inclusion in this directory is not an endorsement.